The arrival of Retatrutide in the United Kingdom is sparking significant excitement within the weight management community. This groundbreaking dual agonist – targeting both GLP-1 and GIP – promises a potentially new solution to addressing obesity . Currently , options have been constrained for many, and Retatrutide represents a promising prosp